-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 12 hour(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 63The 5th Annual OncoAlert Colloquium - 12 hour(s) ago
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Source: oncoalert.m-pages.comCategories: General Medicine News, Oncologists1Tweet-
The #OncoAlertColloquium 🚨Returns for its 5⃣th year The Year in Oncology 2024 with⚕️TOP Oncology Faculty and TOP Oncology Partners that will give this meeting a TRUE Interdisciplinary approach‼️ Registration is NOW OPEN LINK: https://t.co/IZgVZxwIYp See you soon! The Network… https://t.co/841qvpmNCz https://t.co/4Sz69h68aJ
-
-
Mashup Score: 63The 5th Annual OncoAlert Colloquium - 2 day(s) ago
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Source: oncoalert.m-pages.comCategories: General Medicine News, Oncologists1Tweet-
The #OncoAlertColloquium 🚨Returns for its 5⃣th year The Year in Oncology 2024 with⚕️TOP Oncology Faculty and TOP Oncology Partners that will give this meeting a TRUE Interdisciplinary approach‼️ Registration is NOW OPEN LINK: https://t.co/IZgVZxwIYp See you soon! The Network… https://t.co/841qvpmNCz https://t.co/4Sz69h68aJ
-
-
Mashup Score: 19
Antagonistic monoclonal antibodies (mAbs) targeting inhibitory immune checkpoints have revolutionized the field of oncology. CTLA-4, PD-1, and LAG3 are three co-inhibitory receptors, which can be exp…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Oncologists1Tweet-
RT @nataliagandur: 🔬 Checkpoint inhibitors and Fc functions: key findings in oncology immunotherapy 💡: https://t.co/1IpEIYUhIH @OncoAlert…
-
-
Mashup Score: 19
Antagonistic monoclonal antibodies (mAbs) targeting inhibitory immune checkpoints have revolutionized the field of oncology. CTLA-4, PD-1, and LAG3 are three co-inhibitory receptors, which can be exp…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Oncologists1Tweet-
RT @nataliagandur: 🔬 Checkpoint inhibitors and Fc functions: key findings in oncology immunotherapy 💡: https://t.co/1IpEIYUhIH @OncoAlert…
-
-
Mashup Score: 17
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Based on the findings of the EMERALD trial (NCT03778931), which demonstrated significant progression-free survival benefits for elacestrant, the ELCIN trial further explores its efficacy and safety. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
The Phase II ELCIN trial (NCT05596409) Report with Virginia Kaklamani (VJ Onc) https://t.co/NSV2FkCC71 evaluates the efficacy and safety of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Building on the results of the EMERALD trial (NCT03778931),… https://t.co/14Kj3tBMOh https://t.co/iQDOKY7kPc
-
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 4 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet-
RT @BenWestphalen: Out today 💥 The new @OncoAlert 🚨 #newsletter - if you don’t want to miss out: register at https://t.co/AxMKHsMAQC 🌐
-
-
Mashup Score: 17
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Based on the findings of the EMERALD trial (NCT03778931), which demonstrated significant progression-free survival benefits for elacestrant, the ELCIN trial further explores its efficacy and safety. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
The Phase II ELCIN trial (NCT05596409) Report with Virginia Kaklamani (VJ Onc) https://t.co/NSV2FkCC71 evaluates the efficacy and safety of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Building on the results of the EMERALD trial (NCT03778931),… https://t.co/14Kj3tBMOh https://t.co/iQDOKY7kPc
-
-
Mashup Score: 13
Join this webinar on Wednesday 22 January 2025, 19:00-20:00 CET, where Etienne Brain, Evandro de Azambuja, Valentina Guarneri, Cristina Saura and Hans Wildiers will discuss the management of hormone receptor-positive, HER2-negative metastatic breast cancer. EACCME accreditation for attending the live webinar has been applied for.
Source: us02web.zoom.usCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @MirrorsMed for a webinar on Wednesday, 22 January 2025, from 19:00 to 20:00 CET Optimising the management of HR+ HER2- met #BreastCancer SIGN UP HERE https://t.co/WpqVGhyvhl as experts @EtienneB66 @E_de_Azambuja Valentina Guarneri,… https://t.co/aqJPO0biHr https://t.co/cZGLdYrqMW
-
-
Mashup Score: 15SABCS24 ONCOALERT | ONCOBITES - 4 day(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective treatment for TRK fusion breast cancer. Link: https://t.co/k9RIIRx7nl Dr. @ElisaAgostinett Elisa Agostinetto from the Jules Bordet Institute in… https://t.co/YPDzOVivRA https://t.co/I59Ldib4g1
-
RT @BenWestphalen: Out today 💥 The new @OncoAlert 🚨 #newsletter - if you don’t want to miss out: register at https://t.co/AxMKHsMAQC 🌐